Research Article
Laboratory Investigation (2008) 88, 627–633; doi:10.1038/labinvest.2008.30; published online 5 May 2008
Halofuginone upregulates the expression of heparanase in thioacetamide-induced liver fibrosis in rats
Olga Ohayon1, Nidal Mawasi1,5, Anna Pevzner1, Ana Tryvitz1, Tsvia Gildor1, Mark Pines2, Marcos Rojkind3,4, Melia Paizi1 and Gadi Spira1
- 1Department of Anatomy and Cell Biology, The Bruce Rappaport Faculty of Medicine, Technion—Israel Institute of Technology, Haifa, Israel
- 2Institute of Animal Sciences, Agricultural Research Organization, the Volcani Center, Bet Dagan, Israel
- 3Department of Biochemistry and Molecular Biology, George Washington University Medical Center, Washington, DC, USA
- 4Department of Pathology, George Washington University Medical Center, Washington, DC, USA
Correspondence: Assoc. Professor G Spira, PhD, Department of Anatomy and Cell Biology, The Bruce Rappaport Faculty of Medicine, Technion—Israel Institute of Technology, PO Box 9649, Haifa 31096, Israel. E-mail: spira@tx.technion.ac.il
5Contributed equally to as first author.
Received 18 December 2007; Revised 29 January 2008; Accepted 24 February 2008; Published online 5 May 2008.
Abstract
Advanced hepatic fibrosis is characterized by excessive extracellular matrix deposition, where collagen and proteoglycans are the main constituents of scar tissue. In previous studies, we showed that heparanase, a heparan sulfate-degrading enzyme, and vascular endothelial growth factor (VEGF) play an important role during liver development and remodeling. In this communication, we investigated the relationship between heparanase and VEGF in thioacetamide-induced liver fibrosis in rats. Our study shows that heparanase mRNA expression levels correlate with those of VEGF during the induction and recovery stages of liver fibrosis. We further demonstrated that treating fibrotic rat livers with halofuginone (HF), a multipotent antifibrogenic drug, and subsequently subjecting them to hydrodynamics-based transfection with human VEGF-165 resulted in elevated expression of heparanase mRNA. Moreover, these rats demonstrated an improved capacity to regenerate following 70% partial hepatectomy. In vitro, HF stimulated heparanase and VEGF mRNA expression in hepatic stellate cells. Taken together, our results suggest that in addition to the known multiple functions of HF, it also enhances heparanase and VEGF expression and promotes liver regeneration. Accordingly, HF seems to possess ideal properties required to become an excellent antifibrogenic agent in humans.
Keywords:
halofuginone, heparanase, hepatic stellate cells, hydrodynamics-based transfection, rat liver fibrosis, VEGF
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
Identification of IGFBP-6 as an effector of the tumor suppressor activity of SEMA3B
Oncogene Original Article
Laboratory Investigation Research Article
Gene Therapy Original Article
TLR4 enhances TGF-β signaling and hepatic fibrosis
Nature Medicine Article (01 Nov 2007)
Laboratory Investigation Article Response

